Table 34.

Antimicrobial resistance in Campylobacter coli from humans per country in 2016

Country	Gentamicin		Co‐amoxiclav		Ciprofloxacin		Erythromycin		Tetracyclines
	N	% Res	N	% Res	N	% Res	N	% Res	N	% Res
Austria	37	2.7	–	–	37	81.1	37	2.7	37	67.6
Cyprus	–	–	–	–	7	NA	7	NA	7	NA
Estonia	–	–	–	–	19	89.5	19	63.2	19	73.7
Finlanda	–	–	–	–	272	84.6	263	22.8	143	69.2
Franceb	797	1.6	881	0.5	882	67.0	881	6.4	851	77.3
Italy	9	NA	–	–	11	100	11	27.3	11	90.9
Lithuaniab	–	–	–	–	41	92.7	41	17.1	40	80.0
Luxembourg	–	–	53	26.4	53	84.9	53	13.2	53	81.1
Malta	6	NA	6	NA	61	70.5	61	9.8	7	NA
Netherlandsb	–	–	–	–	164	65.2	146	9.6	107	65.4
Portugal	34	0	–	–	34	100	34	50.0	34	91.2
Romania	16	0	16	0	16	31.3	16	0	16	18.8
Slovakiab	1	NA	24	12.5	53	60.4	64	4.7	66	37.9
Slovenia	–	–	–	–	130	66.2	130	2.3	130	47.7
Spain	38	5.3	–	–	38	84.2	38	23.7	38	84.2
United Kingdomb	–	–	–	–	747	44.3	678	11.1	360	35.6
Total (16 MSs)	938	1.7	980	2.7	2,565	63.8	2,479	11.0	1,919	64.8
Icelandb	–	–	–	–	1	NA	1	NA	–	–
Norway	10	0	–	–	10	80.0	10	10.0	10	90.0

N: number of isolates tested; % Res: percentage of resistant isolates (either non‐wild type by ECOFFs or clinically non‐susceptible by combining resistant and intermediate categories); –: no data reported; NA: not applicable (if less than 10 isolates were tested, the percentage of resistance was not calculated).

^aTravel‐associated cases, accounting for 65% of Campylobacter infections in Finland in 2016, could not be excluded from the Finnish AST data.

^bData interpreted with clinical breakpoints.